Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831.

Publication Type:

Journal Article

Authors:

Dueck, Amylou C; Reinholz, Monica M; Geiger, Xochiquetzal J; Tenner, Kathleen; Ballman, Karla; Jenkins, Robert B; Riehle, Darren; Chen, Beiyun; McCullough, Ann E; Davidson, Nancy E; Martino, Silvana; Sledge, George W; Kaufman, Peter A; Kutteh, Leila A; Gralow, Julie; Harris, Lyndsay N; Ingle, James N; Lingle, Wilma L; Perez, Edith A

Source:

Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 19, Issue 20, p.5798-807 (2013)

Keywords:

2013, Clinical Research Division, September 2013

Abstract:

This study investigated the association between tumor MYC protein expression and disease-free survival (DFS) of patients randomized to receive chemotherapy alone (Arm A) or chemotherapy with sequential (Arm B) or concurrent trastuzumab (Arm C) in the N9831 (Alliance) adjuvant HER2(+) trastuzumab breast cancer trial.